军事医学2018，Vol.42Issue(2)：154-157,4.DOI:10.7644/j.issn.1674-9960.2018.02.015
程序性死亡受体-1/配体-1在软组织肉瘤中的研究进展
Research progress of PD-1/PD-L1 in soft tissue sarcoma
李静 1陈建魁 1杨武威1
作者信息
- 1. 军事科学院军事医学研究院附属医院,北京 100071
- 折叠
摘要
Abstract
Programmed cell death-1 ( PD-1 ) is a member of the CD28/cytotoxic T lymphocyte-associated protein-4 (CTLA-4) family, expressed on activated T cells, B cells and macrophages.Programmed cell death-ligand 1 (PD-L1) can inhibit T cell proliferation , activation and cytokine secretion , and participate in the negative feedback regulation of T cell receptor signals.In a normal body, PD-1/PD-Ls signaling pathway plays an important role in maintaining immune tolerance,but can inhibit T cell immune response and promote tumor immune escape in case of tumor .The relationships between the expression and prognosis of PD-1/PD-L1 in soft tissue sarcoma ( STS ) and its biological significance , influencing factors of PD-1/PD-L1 expression , and research progress in related drugs and clinical applicability in STS are reviewed.关键词
程序性死亡受体-1/程序性死亡受体配体-1/软组织肉瘤Key words
programmed death receptor-1/programmed death receptor ligand-1/soft tissue sarcoma分类
医药卫生引用本文复制引用
李静,陈建魁,杨武威..程序性死亡受体-1/配体-1在软组织肉瘤中的研究进展[J].军事医学,2018,42(2):154-157,4.
